Head and Neck Squamous Cell Carcinoma Clinical Trials in Portland, Oregon

4 studies are recruiting for head and neck squamous cell carcinoma in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

   This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chem…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Providence Portland Medical Center, Portland, Oregon

   Locations

   679 in total

   Run by

   ECOG-ACRIN Cancer Research Group

   See if you can join NCT02734537 on ClinicalTrials.gov

2. Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

   This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Oregon Health and Science University, Portland, Oregon

   Locations

   11 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06980038 on ClinicalTrials.gov

3. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

   Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Portland, Oregon

   Locations

   23 in total

   Run by

   AstraZeneca

   See if you can join NCT05877599 on ClinicalTrials.gov

4. Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

   This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for pos…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Providence Cancer Institute, Portland, Oregon

   Locations

   5 in total

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT05977907 on ClinicalTrials.gov